DGAP-News

Biotest AG: ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062)

DGAP-News: Biotest AG / Key word(s): Alliance Biotest AG: ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062) 24.03.2017 / 07:00 The issuer is solely responsible for the content of this announcement. PRESS RELEASE

ImmunoGen has elected not to exercise its late stage co-development option for the US-Market with Biotest's antibody-drug conjugate (BT-062)

- License agreement with ImmunoGen will continue

Dreieich, 24 March 2017. Since 2006 a collaboration and licensing agreement between Biotest and ImmunoGen, Inc., MA (USA) (ImmunoGen) is in place for the use of ImmunoGen's antibody-drug conjugate (ADC) linker and payload technology used with Biotest's development-stage compound Indatuximab Ravtansine (BT-062).

ImmunoGen notified Biotest that they have elected not to exercise a late stage co-development option provided for in the cooperation agreement. For a payment of USD 15 million, ImmunoGen would have opted in to share half of the development and marketing of Indatuximab Ravtansine (BT-062) in the US market. The license agreement with ImmunoGen regarding the use of its linker and payload technology continues unchanged.

The Phase I/IIa study (Study 983) is investigating Indatuximab Ravtansine (BT-062) in combination with lenalidomide or pomalidomide and dexamethasone in patients with multiple myeloma who have not been responding (any more) to previous treatments. Multiple myeloma is a malignant hematologic disease and despite new treatment options patients very often relapse. Biotest presented new clinical data derived from an ongoing combination study with BT-062 in December 2016 at the annual meeting of the American Society of Hematology (ASH). A phase I/II study (study 989) with Indatuximab Ravtansine (BT-062) for the treatment of solid tumors (breast cancer and bladder cancer) is currently being evaluated.